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Withmore than a third of patients expected to endure the arrhythmia at any given time point, atrial fibrillation after cardiac surgery
becomes a vexing problem in the postoperative care of cardiac surgery patients. The impact on patient care covers a spectrum
from the more common clinically insignificant sequelae to debilitating embolic events. Despite this, postoperative atrial fibrillation
generally masquerades as being insignificant, or at most as an anticipated inherent risk, merely extending one’s hospital stay by a
few days. As an independent risk factor for stroke, early and late mortality, and being a multibillion dollar strain on the healthcare
system annually, postoperative atrial fibrillation is far more flagrant than a mere inherent risk. It is a serious medical quandary,
which is not recognized as such.Though complete prevention is unrealistic, a step-wise treatment strategy that incorporatesmultiple
preventativemodalities can significantly reduce the impact of postoperative atrial fibrillation on patient care.The aims of this review
are to present a brief overview of the arrhythmia’s etiology, risk factors, and preventative strategies to reduce associatedmorbidities.
Newer anticoagulants and the potential role of these drugs on future treatment paradigms are also discussed.
1. Introduction
Atrial fibrillation (AF) is the most common arrhythmia and
morbidity after cardiac surgery. Though the incidence varies
depending on the intensity of monitoring, best estimates sug-
gest that nearly 30% of patients undergoing coronary artery
bypass grafting (CABG) surgery, 40% of patients undergoing
valvular heart surgery, and more than the half of all patients
undergoing combined coronary and valvular procedures will
develop the arrhythmia [1, 2]. Although postoperative atrial
fibrillation (POAF) is at times dismissed as a nonissue due
to its often benign course, POAF remains a serious medical
concern. The arrhythmia poses serious risks to patients in
the postoperative period and requires countless preventative
healthcare expenditure [3–10]. This paper is an up-to-date
look into POAF etiology, risk factors, and consequences.
Treatment strategies to reduce the incidence of POAF and
preventative modalities to minimize risk of the arrhythmia
are also discussed. There is currently no single treatment
or preventative option for POAF. A systematic approach
that is initiated in the preoperative period and continued to
the perioperative recovery phase offers the best preventative
strategy. Futuristic anticoagulants and their potential impact
on hospital length of stay and associated hospital costs are
also discussed.
2. Etiology
Though our understanding of the biochemical and cellular
interplays of POAF remains incomplete, the multiple wavelet
re-entry theory has proven a useful model and is generally
regarded as the predominant process [11–13]. Other models,
such as the focal mechanism theory and the mother rotor
theory, have also been described [12–14].
The multiple-wavelet theory hypothesizes that AF is
sustained by multiple, equally dominant, concurrent, and re-
entry circuits, due to an alteration or change in the atrial
substrate. This change in the substrate subsequently slows
the propagation of the forward moving action potential
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through the atrial tissues and results in a unidirectional block.
This phenomenon occurs in conjunction with a shortening
of the refractory period in alternate directions causing the
impulse to take a retrograde course. This single event occurs
in countless repetition creating multiple re-entrant wavelets
through the surmised “atrial dispersion of refractoriness”.
These re-entrant wavelets produce an electrically unstable
environment within the atria that are highly susceptible to
AF. Once present, a triggering event, some initiating force
(i.e., premature atrial contraction) sets the process of AF in
motion. Both the initiating trigger and an altered substrate to
sustain the arrhythmia are required for AF to occur. Specific
to cardiac surgery, there are several variables throughout
the surgical period where both, a triggering event and an
alteration to the atrial substrate, could occur meeting the
necessary conditions for AF to formulate.
The focal mechanism theory hypothesizes that AF is
sustained by rapidly firing focal discharges from the atria,
most likely generated in sleeves of the pulmonary vein [15].
Several mechanisms of ectopic impulse generation (focal
discharges) have been described. These include enhanced
automaticity, delayed afterdepolarizations (DADs), and early
after repolarizations (EADs). These rapid ectopic beats are
dependent upon the slope of phase 4 depolarization. Phase
4 depolarization is the period required to attain threshold
potential thus creating an action potential.The slope of phase
4 could become elevated due to an increased atrial expression
of ion channel subunits. When this occurs, the spontaneous
rate enhances, thus increasing the risk of ectopic discharges
or sustained AF.
Moreover, a distortion in the cellular calcium home-
ostasis, especially calcium overload, can develop DADs.
Delayed afterdepolarizations are impulsive hump-shaped
depolarizations that occur after complete repolarization. Of
note, the mechanism and form of DADs are different from
spontaneous phase 4 depolarization. If these DADs reach
the threshold potential, cell firing occurs either as a single
ectopic beat or as a sustained atrial tachycardia. Calcium
enters the cells through calcium channels with each separate
action potential. Rapid firing rates increase calcium entry and
therefore potentially provoke DAD-related arrhythmias.
In addition, EADs that occur during repolarization
may also induce triggered activity. Early afterdepolariza-
tions result from action potentials that become unusually
extended, which allow calcium channels (𝐼CaL) to recover
from inactivation and generate abnormal depolarizations at
plateau potentials [13].
One of the more novel hypotheses regarding the mecha-
nism of AF is the mother rotor theory. Rotors are described
as key drivers or organizing centres of fibrillation [14]. Unlike
the multiple-wavelet theory, which suggests that AF results
from multiple, equally dominant, and re-entrant circuits, the
mother rotors theory claims that one chief core “mother
re-entrant wave” discards and instigates several “daughter
waves”. Atrial fibrillation is sustained by the mother rotor,
where daughter wavelets originate but disseminate in an
irregular pattern due to fibrillatory conduction. This fibrilla-
tory conduction is caused by a wave break in anatomically
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Figure 1: Schematic illustration of several factors that contribute to
POAF. (postoperative atrial fibrillation = POAF).
determined areas in the atria including pectinate muscles
[14]. It could therefore be plausible that a rotor or even several
rotors are the main drivers that sustain POAF.
Still, from a clinical perspective in the postcardiac
surgery patient, regardless of the exact pathway involved,
alteration in the atrial tissue from the combined impact
of a patient’s preoperative characteristics and perioperative
insults is inevitably thought to be responsible for POAF.
Certain biochemical mechanisms either trigger POAF or
affect the atrial substrate and sustain POAF. Neurohormonal
activation, volume overload, and the complex biochemical
by-products of inflammation each has a role in this regard.
Figure 1 illustrates a schematic overviewof several factors that
contribute to the pathogenesis of POAF.
Neurohormonal activation and an increase in sympa-
thetic stimulant often precede AF implicating this biochemi-
cal pathway as a trigger. Clinically, pain, intraoperative heart
manipulation, hypovolemia, or any additional perioperative
insult causing an upregulation in catecholamines can then
activate adrenoreceptors within the left atrium and heighten
their propensity to engage an electrical response or trigger an
event [16].
Conversely, persistent volume overload is thought to
sustain POAF. Increased volume alters atrial pressures and
atrial compliance. Volume overload has proven to shorten
atrial refractory periods in the atria of animals and humans,
similarly, lending support to its role in changing the atrial
substrate [17, 18].
Clinical evidence supports the relationship between
increased volume and POAF. In a prospective series of
patients undergoing CABG, preoperative left atrial vol-
ume as determined by echocardiography was shown to be
an independent risk factor for the occurrence of POAF
[19]. Moreover, in the second atrial fibrillation suppression
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trial, a net fluid balance on postoperative day 2 was an
independent predictor of POAF [20].
Evidence to implicate inflammation as a major patho-
genesis of POAF continues to build. A recent study of 104
patients undergoing on-pump CABG noted a significant
increase in intraoperative inflammatory plasma biomarkers
prior to cardiopulmonary bypass (high-sensitivity C-reactive
protein and interleukin-6) acquired from the atria of patients
who had POAF as opposed to the patients that remained
in normal sinus rhythm [21]. The study suggests that a pre-
existing intracardiac inflammatory environment predisposes
a patient to POAF. In a canine model, inflammation has
proven to slow the electrical conduction velocity of the action
potential traversing atrial tissue, which supports the re-
entrant wavelet model [22]. Slowing the conduction velocity
results in unidirectional block and sets the stage for re-entrant
wavelets as previously discussed.
These are only a few examples amidst a conglomerate of
conjoined variables in what is known as a complex multifac-
torial process inevitably responsible for causing POAF.
3. Risk Factors
While the underlying biochemical and cellular mechanisms
involved in POAF are highly complex and remain incom-
pletely understood, at the clinical level there are easily
identifiable risk factors that predispose patients to POAF.
These risk factors can be divided into three phases, namely,
preoperative, intraoperative, and postoperativemanagement.
Moreover, these risk factors can be categorized as either being
modifiable or nonmodifiable (Table 1) [3, 10, 23–27]. This
simple schema aids in formulating preventative management
strategies.
Although there are inconsistencies with respect to some
risk factors in the published literature, advanced age is the
single most important and consistently proven factor to
increase a patient’s risk of POAF [23, 28]. Age has shown to
increase the risk of POAF 1.5-fold for each 5-year increment
starting at age 50 up to age 75 [29]. Similarly, in a large
multicenter observational study of 4600 patients, age was
noted to increase the risk of POAF by 75% for each 10-year
increment starting at age 40. The very same study concluded
that all patients aged 70 or older are at high risk for POAF [3].
The various intraoperative and postoperative risk factors
responsible for POAF impose their effects through one of the
following mechanisms: either an upregulation of the body’s
sympathetic response, a slowing of the conduction velocity
with atrial stretch or by inducing an inflammatory cascade.
Myocardial ischemia, atrial cannulation, aortic cross-clamp
time, left ventricular venting, hyper and hypovolemic states,
damage to the atrium, endotracheal tube insertion, excess
inotropic requirements, and electrolyte imbalances are snap-
shots into the various factors published in the literature
as potential predictors for POAF [3, 10, 11, 16, 17, 30].
Extracorporeal circulation and its impact on POAF in CABG
are important topics that remain controversial. Several meta-
analyses have consistently shown substantial reductions in
the occurrence of POAFwith off-pumpCABG in comparison
to on-pump procedures [24, 31, 32]. However the largest ran-
domized controlled trial (RCT) to date comparing outcomes
between on and off-pump CABG procedure on over 4,700
patients showed no difference in POAF amongst the two
groups (OR 1.02; 95%CI 0.9 to 1.15; 𝑃 = 0.72) [33].
4. Morbidity, Mortality, and
Anticoagulant Therapy
Generally, POAF is considered a transient, self-limiting event
that is well tolerated with no discernible effects during the
postoperative course. However, this is not always the case,
as the presence of POAF can have a deleterious effect on
patient recovery and impact patient care in a variety of ways.
Patients may experience fatigue, palpitations, or diaphoresis,
which is of significant discomfort for them. Or at the other
extreme, acute hypotension and hemodynamic instability
may be the initial presentation, necessitating immediate
cardioversion [34]. Most importantly, POAF increases one’s
thromboembolic loadwhich is associatedwith stroke risk and
increases a patient’s mortality.
Strokes can be catastrophic and significantly impact
quality of life and long-term survival [35]. The incidence
of stroke in patients who develop POAF following cardiac
surgery is 3-fold higher than it is in patients who remain
in normal sinus rhythm [25]. Moreover, not only does an
early postoperative stroke affect early mortality, but it also
affects late mortality as well [30]. In a study of more than
16,000 patients undergoing CABG, POAF was also found to
incur a 21% relative increase in late mortality (mean 6-year
followup) [10]. Similar results have been reported in a recent
observational study from Australia on over 19,000 patients
[36]. This would suggest that the presence of the arrhythmia
is at the very least a marker for long-term mortality.
The cornerstone of treating POAF is the preventative
strategy that will increase the likelihood of maintaining
normal sinus rhythm for the duration of the postoperative
course. These varied preventative strategies are discussed
later in the paper.
For patients who fail preventative therapy, standard treat-
ment with rate control and anticoagulation should be insti-
tuted to minimize complications. In general, the treatment
of patients with POAF is similar to treatment of nonsurgical
patients who develop AF.The primary goal is anticoagulation
with rate control. The atrial fibrillation follow-up investi-
gation of rhythm management trial (AFFIRM), a clinical
trial on over 4,000 patients, showed that there was no
difference in mortality between patients with chronic AF
treated with anticoagulation and rate control in comparison
to anticoagulation and rhythm control (HR 1.15; 95%CI
0.99 to 1.34; 𝑃 = 0.08). The utilization of antiarrhythmic
agents for rhythm control was associated with more drug
induced adverse effects including an increased risk for cardiac
depression and torsade de pointes [37].TheAmericanCollege
of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines (ACC/AHA) therefore recom-
mends the administration of AV nodal blocking agents to
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Table 1: Pre-, intra-, and postoperative (nonmodifiable and modifiable) clinical risk factors associated with POAF.
Preoperative risk factors Intraoperative risk factors Postoperative risk factors
Nonmodifiable risk factors Nonmodifiable risk factors Nonmodifiable risk factors
High age Endotracheal tube insertion Return to intensive care unit
Male gender Intraoperative IABP Ventilation longer than 24 hours
Previous cardiac surgery Left ventricular venting Modifiable risk factors
Valvular heart disease Aortic cross-clamp time Volume overload
Chronic lung disease Extracorporeal circulation Pneumonia
Chronic renal failure Myocardial ischemia Electrolyte imbalances
Left atrium enlargement Venous cannulation Imbalance of the autonomic nervous system
Left ventricular hypertrophy Modifiable risk factors Atrial extrasystole
Modifiable risk factors Damage to the atrium Increased postoperative adrenergic status
Withdrawal of 𝛽-blocker medication Excess inotropic requirements Increased afterload
History of AF Acute volume change Inflammation
Hypertension Hypotension
Obesity
Diabetes
Metabolic syndrome
IABP: Intra-Aortic Balloon Pump.
achieve rate control in patients who develop POAF (class I;
level B) [34].
When POAF persists for more than 48 hours, both the
AmericanCollege of Chest Physicians and theAmericanCol-
lege of Cardiology Foundation recommend anticoagulation
for 30 days with a vitamin K antagonist (warfarin) to achieve
an international normalizing ratio between 2.0 and 3.0 [34,
38]. Bridging with intravenous heparin is only recommended
for high-risk patients who had a prior thromboembolic event.
These recommendations need to be implemented in the
context of each individuals bleeding risk with respect to
anticoagulation administration in the postoperative period
[34, 38].
Warfarin therapy is the long-term anticoagulant of choice
for POAF and has remained so since its introduction.
Although it has proven to be effective at reducing the risk of
stroke, warfarin’s variable dose response, narrow therapeutic
index, various drug and food interactions, frequent testing
requirements, and poor patient compliance are some of the
medications many shortcomings. New oral anticoagulants
with more favourable risk profiles, specifically the direct
thrombin inhibitor, dabigatran, and the direct factor Xa
inhibitor, rivaroxaban and apixaban, were recently approved
by Food and Drug Administration (FDA) in the United
States for the treatment of stroke and systemic embolism in
nonvalvular atrial fibrillation. In a clinical trial where 18,000
patients with nonvalvular AF were randomized to dabigatran
or adjusted-dose warfarin, twice daily dosing of dabigatran
at 150mg reduced the risk of stroke or peripheral embolic
events by 34% (RR 0.66; 95%CI 0.53 to 0.82; 𝑃 < 0.001)
while showing no increase in bleeding risk (RR 0.93; 95%CI
0.81 to 1.07; 𝑃 = 0.31) [39]. In addition to this, dabigatran
does not demonstrate an interaction with other drugs, does
not necessitate regular monitoring, and has a short half-
life. Based largely on this data, dabigatran has recently been
given a class I recommendation by the American College
of Cardiology Foundation for the treatment on nonvalvular
AF [40]. Similarly, rivaroxaban at a once daily dose of
20mg reduced the risk of stroke and peripheral embolic
events by 21% (RR 0.79; 95%CI 0.66 to 0.96) with similar
bleeding profiles when compared to adjusted-dose warfarin
in a RCT of 14,000 patients with nonvalvular AF [41]. Also, a
RCT (ARISTOTLE trial) with a mean follow-up of 1.8 years
involving 18,201 patients with AF and at least one additional
risk factor for stroke were randomized to receive either
apixaban at a twice daily dose of 5mg or warfarin (INR 2.0 to
3.0). Up to 62% of the patients achieved the therapeutic INR
range. In addition, both cohort arms permitted up to 162mg
of aspirin. The trial demonstrated a significant reduction
in favour of apixaban with regard to stroke or systematic
embolism (HR 0.79; 95%CI 0.66 to 0.95 𝑃 = 0.01), major
bleeding (HR 0.69; 95%CI, 0.60 to 0.80; 𝑃 < 0.001), and
mortality (HR 0.89; 95%CI, 0.80 to 0.99; 𝑃 = 0.047) [42].
However, none of these trials included patients under-
going cardiac surgery. To that end, neither the results from
these trials can be generalized to themanagement of POAF in
cardiac surgery nor have these anticoagulants been approved
for such an indication. Nonetheless, the results from these
trials pave the way for future studies to assess the risk-
benefit ratio of these medications for the cardiac surgery
population. Since the time required to achieve therapeutic
levels of warfarin is known to significantly increase hospital
length of stay, one could speculate that the use of these
newer anticoagulants with their immediate onset of action
could substantially reduce hospital stay and in turn reduce
hospital costs [23]. Moreover, if these new anticoagulants
could prove to reduce stroke and bleeding in the POAF
population, the reduction in costs could be substantial. Yet,
the current cost of dabigatran is 18 times that of warfarin
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($9/day versus $0.50/day), which would mitigate some of its
cost-effectiveness.
5. Preventative Strategies
Pharmacotherapy is the mainstay preventative measure to
reduce the incidence of POAF. Several different drugs have
been utilized in various combinations and studied at various
stages in the perioperative period with different doses and
routes of administration. The various combinations have
made it difficult to find the best approach for preventing
POAF. Currently,𝛽-Blockers, amiodarone, and sotalol are the
three most commonly used medications to prevent POAF.
Upstream therapies including statins, magnesium, and
corticosteroids are less widely used but there is evidence to
support their utilization. Several intraoperative prophylaxes
have also been utilized to reduce the incidence of POAF,
including atrial pacing and posterior pericardiotomy. Tables
2, 3, and 4 select the best evidencemeta-analyses and RCTs to
support the use of these medications and nonpharmaceutical
interventions.
5.1. Nonpharmacological Prophylactic Interventions
5.1.1. Posterior Pericardiotomy. Non-pharmacologic interven
tions have become attractive preventative strategies for AF
after cardiac surgery because of the absence of drug-induced
adverse events. Posterior pericardiotomy is an intraoper-
ative intervention in which generally a 4 cm longitudinal
incision is made posterior in the pericardium and parallel
to the phrenic nerve. Blood effusion in the pericardium
could induce cardiac irritation which is a risk factor for
developing POAF. The rationale for this procedure is mainly
that this technique allows postoperative fluid drainage, thus
preventing pericardial effusion [26, 27]. A meta-analysis of 6
studies involving 763 patients showed a significant reduction
in POAF with an absolute risk reduction of 19% in the
posterior pericardiotomy group (OR 0.35; 95%CI 0.18 to
0.67; 𝑃 = 0.001; Number needed to harm (NNH) = 6)
[43]. Another meta-analysis of 6 studies in 763 patients
undergoing a CABG surgery confirmed this result (OR 0.33;
95%CI 0.16 to 0.69; 𝑃 = 0.003; NNT = 6) [44]. However,
posterior pericardiotomy was not associated with reduction
in postoperative mortality rate or length of hospital stay [43].
A potential complication of this surgical procedure is
the possible risk of cardiac herniation. Bypass grafts after
a CABG procedure can obtrude and could potentially be
compressed by the edges of the posterior pericardiotomy.
A partial posterior pericardiotomy incision distant from the
bypass graft limits the risk of this complication. [59]. There
is also a risk of phrenic nerve injury which can be limited by
direct visualization.
The present data shows that posterior pericardiotomy is
an effectivemethod, although the evidence level is not strong.
It also lacks other morbidity data such as stroke, reopera-
tion, postoperative hemodynamic instability, and pericardial
effusion. Therefore, it still remains controversial whether
this surgical procedure should be utilized as a standard
prophylactic intervention.
5.1.2. Atrial Pacing. Atrial pacing controls the cardiac rate via
electrical stimulation. Prevention of POAF could be achieved
by restraining atrial premature beats. Unlike pharmacological
prophylaxis, pacing prophylaxis is not associated with the
risk of developing bradycardia or hypotension. Additionally,
pacing therapy has the advantage that it does not need to
be initiated before cardiac surgery in contrast to most of the
pharmacological prophylaxis.
Multiple pacing strategies have been utilized to prevent
POAF. These include left atrial pacing, right atrial pacing,
biatrial pacing, and Bachmann’s bundle pacing. A meta-
analysis of 14 studies in 1846 patients analyzed the relation-
ship between atrial pacing and prevention of POAF. Only
biatrial pacing showed a significant result with regard to
shorter length of stay and risk reduction of POAF (OR
0.44, 95%CI 0.31 to 0.64; 𝑃 < 0.001; NNT = 7). Other
pacing configurations did not show a significant outcome in
reducing POAF [45].
A more recent meta-analysis of 21 studies involving
2633 patients showed a favourable outcome for atrial pacing
with regard to prevention of POAF and length of stay
(OR 0.47; 95%CI 0.36 to 0.61; 𝑃 < 0.00001; NNT = 8).
This meta-analysis was a pooled analysis of all atrial pacing
techniques. Despite these results, atrial pacing was not asso-
ciated with risk reduction for stroke, cardiovascularmortality
or a decrease in hospital costs [43, 45]. A potential side
effect of pacing therapy is the risk of malfunctioning atrial
leads or inappropriate sensing, which could potentially cause
proarrhythmic atrial extrastimulation, thus increasing the
likelihood of arrhythmias.
Atrial pacing therapy, especially biatrial pacing seems
to be an effective strategy in preventing POAF and should
therefore be considered an option for prevention of POAF if
patients have a contraindication for pharmacological prophy-
laxis, especially 𝛽-Blockers and amiodarone therapy.
5.2. Pharmacological Prophylactic Interventions
5.2.1. 𝛽-Blocker Therapy. 𝛽-Blockers are class II antiarrhyth-
mic drugs and have antiarrhythmic action on both myocar-
dial and stimulus conduction cells. 𝛽-Blocker therapy is
considered the most successful prophylaxis therapy in regard
to POAF prevention. A risk factor for developing POAF is
the withdrawal of 𝛽-blocker therapy; therefore this should
be avoided whenever possible. A recent meta-analysis of
10 studies involving 2,556 patients who underwent CABG
demonstrated a reduction in POAF in the 𝛽-blocker therapy
group (OR 0.50; 95%CI 0.36 to 0.69; 𝑃 < 0.001; NNT = 8).
The vast majority of the patients received 𝛽-Blocker therapy
within 24 hours after cardiac surgery [46]. A similar meta-
analysis of 33 studies involving 4,698 patients who underwent
either valve and/or CABG surgery has also demonstrated that
𝛽-blocker therapy reduced the incidence of POAF with an
absolute risk ratio of 15.4% (OR 0.33; 95%CI 0.26 to 0.43; 𝑃 <
0.00001; NNT= 7) [43]. However, no risk reduction in stroke,
postoperative mortality, cardiovascular mortality, and length
of hospital stay was observed [43, 45].The prophylactic effect
of 𝛽-blocker therapy is the highest when given both before
and after cardiac surgery when compared to only before or
6 Cardiology Research and Practice
Ta
bl
e
2:
O
ve
rv
ie
w
of
th
ei
nc
lu
de
d
no
np
ha
rm
ac
ol
og
ic
al
stu
di
es
.
In
te
rv
en
tio
n
Au
th
or
Re
f.
Ye
ar
D
es
ig
n
O
ut
co
m
es
of
in
te
re
st
St
ud
y
N
D
es
ig
n
Pa
tie
nt
sN
Re
su
lts
P
va
lu
e
N
N
T
(9
5%
CI
)
Bo
tto
m
lin
e
In
te
rv
en
tio
n
C
on
tro
l
O
dd
sr
at
io
(9
5%
CI
)
Po
ste
rio
rp
er
i-
ca
rd
io
to
m
y
A
rs
en
au
lt
et
al
.
[4
3]
20
13
M
A
PO
A
F
6
RC
Ts
37
9
38
4
0.
35
(0
.18
to
0.
67
)
0.
00
1
6
(4
–8
)
Po
ste
rio
rp
er
ic
ar
di
ot
om
y
is
be
ne
fic
ia
l
Le
ng
te
of
ho
sp
ita
ls
ta
y
3
RC
Ts
22
9
23
4
0.
57
da
ys
(−
1.9
9
to
3.
12
)
0.
66
N
A
N
o
de
cr
ea
se
in
le
ng
te
of
ho
sp
ita
ls
ta
y
M
or
ta
lit
y
1R
CT
10
0
10
0
1.0
0
(0
.0
6
to
16
.4
4)
1.0
0
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
m
or
ta
lit
y
Bi
an
ca
ri
an
d
M
ah
ar
[4
4]
20
10
M
A
PO
A
F
6
RC
Ts
37
9
38
4
0.
33
(0
.16
to
0.
69
)
0.
00
3
6
(4
–8
)
Po
ste
rio
rp
er
ic
ar
di
ot
om
y
is
be
ne
fic
ia
l
At
ria
lp
ac
in
g
A
rs
en
au
lt
et
al
.
[4
3]
20
13
M
A
PO
A
F
21
RC
Ts
14
46
14
87
0.
47
(0
.3
6
to
0.
61
)
<
0.
00
00
1
8
(6
–9
)
At
ria
lp
ac
in
g
is
be
ne
fic
ia
l
St
ro
ke
6
RC
Ts
41
9
41
3
0.
72
(0
.3
6
to
1.4
6)
0.
36
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
str
ok
e
CV
m
or
ta
lit
y
2
RC
Ts
98
10
0
0.
0
(0
.0
to
0.
0)
<
0.
00
00
1
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
CV
m
or
ta
lit
y
Le
ng
th
of
sta
y
18
RC
Ts
74
2
78
3
−
1.1
3
da
ys
(−
1.7
2
to
−
0.
55
)
0.
00
01
5
N
A
Sh
or
te
rl
en
gt
h
of
sta
y
Bu
rg
es
se
ta
l.
[4
5]
20
06
M
A
PO
A
F
14
RC
Ts
92
3
96
2
0.
60
(0
.4
7–
0.
77
)
<
0.
00
1
8
(6
–9
)
At
ria
lp
ac
in
g
is
be
ne
fic
ia
l
PO
A
F
in
bi
at
ria
lg
ro
up
10
RC
Ts
36
7
38
7
0.
44
(0
.31
–0
.6
4)
<
0.
00
1
7
(5
–1
0)
Bi
at
ria
lp
ac
in
g
is
be
ne
fic
ia
l
St
ro
ke
5
RC
Ts
26
8
28
2
0.
61
(0
.2
0
to
1.9
)
0.
48
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
str
ok
e
Le
ng
th
of
sta
y
5
RC
Ts
26
8
28
2
−
1.3
da
ys
(−
2.
55
to
−
0.
08
)
0.
04
N
A
Sh
or
te
rl
en
gt
h
of
st
ay
PO
A
F:
po
sto
pe
ra
tiv
ea
tr
ia
lfi
br
ill
at
io
n;
N
A
:n
ot
ap
pl
ic
ab
le
;N
N
T:
nu
m
be
rn
ee
de
d
to
tre
at
;N
N
H
:n
um
be
rn
ee
de
d
to
ha
rm
;h
rs
:h
ou
rs
;r
ef
.:
re
fe
re
nc
e;
po
sto
p:
po
sto
pe
ra
tiv
e;
pr
eo
p:
pr
eo
pe
ra
tiv
e;
RC
T:
ra
nd
om
iz
ed
co
nt
ro
lt
ria
l;
M
A
:m
et
a-
an
al
ys
is.
Cardiology Research and Practice 7
Ta
bl
e
3:
O
ve
rv
ie
w
of
th
ei
nc
lu
de
d
ph
ar
m
ac
ol
og
ic
al
stu
di
es
.
D
ru
g
Au
th
or
Re
f.
Ye
ar
D
es
ig
n
O
ut
co
m
es
of
in
te
re
st
St
ud
y
N
D
es
ig
n
Pa
tie
nt
sN
Re
su
lts
P
va
lu
e
N
N
T
(9
5%
CI
)
Bo
tto
m
lin
e
In
te
rv
en
tio
n
C
on
tro
l
O
dd
sR
at
io
(9
5%
CI
)
𝛽
-B
lo
ck
er
s
A
rs
en
au
lt
et
al
.
[4
3]
20
13
M
A
PO
A
F
33
RC
Ts
22
94
24
04
0.
33
(0
.2
6
to
0.
43
)
<
0.
00
00
1
7
(6
–8
)
𝛽
-B
lo
ck
er
sa
re
be
ne
fic
ia
l
St
ro
ke
5
RC
Ts
77
4
78
0
1.3
4
(0
.4
6
to
3.
93
)
0.
59
81
(4
3−
50
5)
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
str
ok
e
M
or
ta
lit
y
16
RC
Ts
13
29
13
42
0.
87
(0
.3
4
to
2.
22
)
0.
70
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
m
or
ta
lit
y
CV
m
or
ta
lit
y
11
RC
Ts
10
03
10
08
0.
98
(0
.10
to
9.6
6)
0.
99
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
CV
m
or
ta
lit
y
Le
ng
th
of
sta
y
6
RC
Ts
84
4
83
2
−
0.
74
da
ys
(−
1.4
8
to
0.
00
)
0.
04
9
N
A
Sh
or
te
rl
en
gt
h
of
sta
y
K
ha
n
et
al
.
[4
6]
20
13
M
A
PO
A
F
10
RC
Ts
12
80
12
76
0.
50
(0
.3
6
to
0.
69
)
<
0.
00
1
8
(6
–1
1)
𝛽
-B
lo
ck
er
sa
re
be
ne
fic
ia
l
A
m
io
da
ro
ne
A
rs
en
au
lt
et
al
.
[4
3]
20
13
M
A
PO
A
F
33
RC
Ts
26
03
27
99
0.
43
(0
.3
4
to
0.
54
)
<
0.
00
00
1
8
(6
–9
)
A
m
io
da
ro
ne
is
be
ne
fic
ia
l
St
ro
ke
14
RC
Ts
15
23
15
64
0.
60
(0
.3
5
to
1.0
2)
0.
06
1
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
str
ok
e
M
or
ta
lit
y
23
RC
Ts
20
45
21
32
1.0
8
(0
.74
to
1.5
6)
0.
70
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
m
or
ta
lit
y
CV
m
or
ta
lit
y
14
RC
Ts
12
62
12
53
0.
93
(0
.4
6
to
1.8
6)
0.
83
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
CV
m
or
ta
lit
y
Le
ng
th
of
sta
y
20
RC
Ts
17
16
17
81
−
0.
95
da
ys
(−
1.3
7
to
−
0.
52
)
0.
00
00
13
N
A
Si
gn
ifi
ca
nt
de
cr
ea
se
in
len
gt
h
of
st
ay
Ch
at
te
rje
e
et
al
.
[4
7]
20
13
M
A
PO
A
F
(o
ra
l-o
nl
y)
8
RC
Ts
96
1
94
5
0.
59
(0
.4
9
to
0.
70
)
<
0.
00
00
1
8
(6
–1
1)
A
m
io
da
ro
ne
is
be
ne
fic
ia
l
PO
A
F
(iv
.)
15
RC
Ts
10
52
99
2
0.
57
(0
.4
8
to
0.
75
)
<
0.
00
00
1
8
(6
–1
0)
PO
A
F
in
de
pe
nd
en
tw
ith
re
ga
rd
to
th
er
ou
te
,
PO
A
F
pr
eo
p
ad
m
in
ist
ra
tio
n
11
RC
Ts
114
6
10
67
0.
55
(0
.4
6
to
0.
65
)
<
0.
00
00
1
7
(5
–8
)
tim
in
g
of
dr
ug
ad
m
.,
an
d
du
ra
tio
n
of
tre
at
m
en
t
PO
A
F
po
sto
p
ad
m
in
ist
ra
tio
n
12
RC
Ts
86
7
85
0
0.
50
(0
.33
to
0.
75
)
0.
00
09
9
(6
–1
4)
8 Cardiology Research and Practice
Ta
bl
e
3:
C
on
tin
ue
d.
D
ru
g
Au
th
or
Re
f.
Ye
ar
D
es
ig
n
O
ut
co
m
es
of
in
te
re
st
St
ud
y
N
D
es
ig
n
Pa
tie
nt
sN
Re
su
lts
P
va
lu
e
N
N
T
(9
5%
CI
)
Bo
tto
m
lin
e
In
te
rv
en
tio
n
C
on
tro
l
O
dd
sR
at
io
(9
5%
CI
)
A
rs
en
au
lt
et
al
.
[4
3]
20
13
M
A
PO
A
F
11
RC
Ts
79
9
81
0
0.
34
(0
.2
6
to
0.
43
)
<
0.
00
00
1
5
(4
–6
)
So
ta
lo
li
sb
en
efi
ci
al
St
ro
ke
1R
CT
63
65
0.
34
(0
.0
1t
o
8.
47
)
0.
51
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
str
ok
e
CV
m
or
ta
lit
y
7
RC
Ts
47
5
48
9
0.
0
(0
.0
to
0.
0)
<
0.
00
00
1
N
A
N
o
sig
ni
fic
an
td
ec
re
as
ei
n
CV
m
or
ta
lit
y
Le
ng
th
of
sta
y
7
RC
Ts
45
5
45
6
−
0.
39
da
ys
(−
0.
77
to
−
0.
02
)
0.
04
0
N
A
Sh
or
te
rl
en
gt
h
of
sta
y
So
ta
lo
l
Ke
rin
an
d
Ja
co
b
[4
8]
20
11
M
A
PO
A
F
(s
ot
al
ol
ve
rs
us
pl
ac
eb
o)
5
RC
Ts
48
9
49
9
0.
55
(0
.4
5
to
0.
67
)
<
0.
00
1
6
(4
–8
)
So
ta
lo
li
sb
en
efi
ci
al
PO
A
F
(s
ot
al
ol
ve
rs
us
no
tre
at
m
en
t)
6
RC
Ts
30
4
31
1
0.
33
(0
.2
4
to
0.
46
)
<
0.
00
1
4
(3
–5
)
Sh
or
te
rl
en
gt
h
of
sta
y
PO
A
F
(s
ot
al
ol
ve
rs
us
𝛽
-b
lo
ck
er
)
6
RC
Ts
48
8
55
5
0.
60
(0
.5
0
to
0.
84
)
<
0.
00
1
12
(8
–2
8)
PO
A
F
pr
eo
p
ad
m
in
ist
ra
tio
n
5
RC
Ts
38
9
40
0
0.
55
(0
.4
5
to
0.
68
)
<
0.
00
1
4
(3
–5
)
PO
A
F
po
sto
p
ad
m
in
ist
ra
tio
n
6
RC
Ts
40
4
41
0
0.
39
(0
.2
9
to
0.
51
)
<
0.
00
1
5
(3
–5
)
Le
ng
th
of
sta
y
5
RC
Ts
33
9
34
9
−
0.
5
da
ys
(−
1.0
6
to
−
0.
05
)
<
0.
07
2
N
A
PO
A
F:
po
sto
pe
ra
tiv
ea
tr
ia
lfi
br
ill
at
io
n;
N
A
:n
ot
ap
pl
ic
ab
le
;N
N
T:
nu
m
be
rn
ee
de
d
to
tre
at
;N
N
H
:n
um
be
rn
ee
de
d
to
ha
rm
;r
ef
.:r
ef
er
en
ce
;p
os
to
p:
po
sto
pe
ra
tiv
e;
pr
eo
p:
pr
eo
pe
ra
tiv
e;
iv.
:in
tr
av
en
ou
s;
RC
T:
ra
nd
om
iz
ed
co
nt
ro
lt
ria
l;
M
A
:m
et
a-
an
al
ys
is.
Cardiology Research and Practice 9
Ta
bl
e
4:
O
ve
rv
ie
w
of
th
ei
nc
lu
de
d
up
st
re
am
th
er
ap
y
stu
di
es
.
D
ru
g
Au
th
or
Re
f.
Ye
ar
D
es
ig
n
O
ut
co
m
es
of
In
te
re
st
St
ud
y
N
D
es
ig
n
Pa
tie
nt
sN
Re
su
lts
P
va
lu
e
N
N
T
(9
5%
CI
)
Bo
tto
m
lin
e
In
te
rv
en
tio
n
C
on
tro
l
O
dd
sR
at
io
(9
5%
CI
)
M
ag
ne
siu
m
A
rs
en
au
lt
et
al
.
[4
3]
20
13
M
A
PO
A
F
21
RC
Ts
15
67
14
21
0.
55
(0
.4
1t
o
0.
73
)
<
0.
00
01
11
(8
–1
5)
M
ag
ne
siu
m
is
be
ne
fic
ia
l
St
ro
ke
3
RC
Ts
38
0
38
0
0.
33
(0
.0
3
to
3.
20
)
0.
34
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
st
ro
ke
M
or
ta
lit
y
12
RC
Ts
90
7
85
7
0.
83
(0
.31
to
2.
24
)
0.
72
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
m
or
ta
lit
y
CV
m
or
ta
lit
y
9
RC
Ts
50
2
46
0
0.
53
(0
.0
9
to
3.
13
)
0.
49
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
CV
m
or
ta
lit
y
Le
ng
th
of
sta
y
9
RC
Ts
79
8
79
1
0.
05
da
ys
(−
0.
47
to
0.
57
)
0.
86
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
le
ng
th
of
st
ay
Sh
ep
he
rd
et
al
.
[4
9]
20
08
M
A
PO
A
F
15
RC
Ts
10
70
10
31
0.
65
(0
.53
to
0.
79
)
<
0.
00
01
13
(8
–2
2)
M
ag
ne
siu
m
is
be
ne
fic
ia
l
St
at
in
s
Li
ak
op
ou
lo
s
et
al
.
[5
0]
20
12
M
A
PO
A
F
11
RC
Ts
42
2
41
9
0.
40
(0
.2
9
to
0.
55
)
<
0.
00
00
1
7
(4
–9
)
St
at
in
sa
re
be
ne
fic
ia
l
M
or
ta
lit
y
1R
CT
10
1
99
0.
98
(0
.14
to
7.1
0)
0.
98
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
m
or
ta
lit
y
St
ro
ke
2
RC
Ts
13
3
13
1
0.
70
(0
.14
to
3.
63
)
0.
67
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
st
ro
ke
IC
U
sta
y
7
RC
Ts
26
3
25
8
−
3.
39
hr
s(
−
5.
77
to
−
1.0
1)
0.
00
52
N
A
Sh
or
te
rI
CU
an
d
le
ng
th
of
sta
y
Le
ng
th
of
sta
y
8
RC
Ts
44
2
43
5
−
0.
48
da
ys
(−
0.
85
to
−
0.
11
)
0.
01
1
N
A
Ch
op
ra
et
al
.
[5
1]
20
12
M
A
PO
A
F
9
RC
Ts
46
7
46
6
0.
56
(0
.4
5
to
0.
69
)
<
0.
00
01
7
(5
–9
)
St
at
in
sa
re
be
ne
fic
ia
l
Ch
en
et
al
.
[5
2]
20
10
M
A
PO
A
F
8
RC
Ts
32
6
32
5
0.
57
(0
.4
5–
0.
72
)
0.
00
06
6
(4
–1
0)
St
at
in
sa
re
be
ne
fic
ia
l
IC
U
sta
y
5
RC
Ts
16
7
16
4
−
0.
17
hr
s(
−
0.
37
to
0.
03
)
N
A
N
A
Sh
or
te
rI
CU
an
d
le
ng
th
of
sta
y
Le
ng
th
of
sta
y
6
RC
Ts
68
7
−
0.
66
da
ys
(−
1.0
1t
o
−
0.
30
)
N
A
N
A
10 Cardiology Research and Practice
Ta
bl
e
4:
C
on
tin
ue
d.
D
ru
g
Au
th
or
Re
f.
Ye
ar
D
es
ig
n
O
ut
co
m
es
of
In
te
re
st
St
ud
y
N
D
es
ig
n
Pa
tie
nt
sN
Re
su
lts
P
va
lu
e
N
N
T
(9
5%
CI
)
Bo
tto
m
lin
e
In
te
rv
en
tio
n
C
on
tro
l
O
dd
sR
at
io
(9
5%
CI
)
C
or
tic
os
te
ro
id
s
H
o
an
d
Ta
n
[5
3]
20
09
M
A
PO
A
F
17
RC
Ts
75
2
75
7
0.
74
(0
.6
3
to
0.
86
)
0.
00
01
10
(7
–1
9)
C
or
tic
os
te
ro
id
sa
re
be
ne
fic
ia
l
In
fe
ct
io
n
22
RC
Ts
80
6
80
2
0.
93
(0
.6
1t
o
1.4
1)
0.
73
N
A
N
o
in
cr
ea
se
in
in
fe
ct
io
n
(b
ut
m
or
e
hy
pe
rg
ly
ce
m
ia
ne
ed
in
g
in
su
lin
,2
8%
RR
)
M
or
ta
lit
y
35
RC
Ts
14
07
13
79
0.
72
(0
.4
5
to
1.1
4)
0.
16
N
A
In
cr
ea
se
d
hy
pe
rg
ly
ce
m
ia
w
he
n
ut
ili
za
tio
n
of
hi
gh
do
se
s
H
yp
er
gl
yc
em
ia
9
RC
Ts
25
5
24
8
1.4
9
(1
.11
to
2.
01
)
0.
00
9
N
N
H
=
9
(5
–2
5)
D
os
ed
id
no
ta
ffe
ct
th
e
ou
tc
om
e
D
ie
le
m
an
et
al
.
[5
4]
20
11
M
A
PO
A
F
17
RC
Ts
69
4
69
5
0.
60
(0
.4
6
to
0.
78
)
0.
00
01
6
13
(8
–2
8)
C
or
tic
os
te
ro
id
sa
re
be
ne
fic
ia
l
St
ro
ke
10
RC
Ts
53
8
51
4
0.
70
(0
.33
to
1.4
8)
0.
35
N
A
N
o
sig
ni
fic
an
ti
m
pa
ct
on
str
ok
e,
m
or
ta
lit
y,
M
or
ta
lit
y
17
RC
Ts
10
36
97
6
1.1
2
(0
.6
5
to
1.9
2)
0.
68
N
A
an
d
in
fe
ct
io
ns
In
fe
ct
io
ns
15
RC
Ts
74
4
74
3
0.
86
(0
.5
6
to
1.3
1)
0.
47
N
A
Sh
or
te
rI
CU
an
d
ho
sp
ita
ls
ta
y
IC
U
sta
y
25
RC
Ts
60
5
61
0
−
2.
32
hr
s(
−
2.
84
to
−
1.8
1)
<
0.
00
00
1
N
A
H
os
pi
ta
ls
ta
y
15
RC
Ts
31
2
31
3
−
0.
40
da
ys
(−
0.
65
to
−
0.
15
)
0.
00
17
N
A
D
ie
le
m
an
et
al
.
[5
5]
20
12
RC
T
PO
A
F
1R
CT
22
35
22
47
0.
94
(0
.8
7
to
1.0
2)
0.
14
N
A
C
or
tic
os
te
ro
id
sa
re
no
t
be
ne
fic
ia
l
St
ro
ke
1R
CT
22
35
22
47
0.
91
(0
.5
5
to
1.5
0)
0.
72
N
A
D
ec
re
as
ed
ris
k
of
in
fe
ct
io
n
M
or
ta
lit
y
1R
CT
22
35
22
47
0.
92
(0
.5
7
to
1.4
9)
0.
73
N
A
N
o
sig
ni
fic
an
ti
m
pa
ct
on
str
ok
e
In
fe
ct
io
n
1R
CT
22
35
22
47
0.
64
(0
.5
4
to
0.
75
)
<
0.
00
1
19
(14
–2
9)
N
o
sig
ni
fic
an
ti
m
pa
ct
on
m
or
ta
lit
y
Le
ng
th
of
sta
y
1R
CT
22
35
22
47
N
A
0.
00
9
N
A
Sh
or
te
rI
CU
an
d
ho
sp
ita
ls
ta
y
IC
U
sta
y
1R
CT
22
35
22
47
N
A
<
0.
00
1
N
A
In
cr
ea
se
d
ris
k
of
hy
pe
rg
ly
ce
m
ia
H
yp
er
gl
yc
em
ia
1R
CT
22
35
22
47
N
A
<
0.
00
1
N
A
Cardiology Research and Practice 11
Ta
bl
e
4:
C
on
tin
ue
d.
D
ru
g
Au
th
or
Re
f.
Ye
ar
D
es
ig
n
O
ut
co
m
es
of
In
te
re
st
St
ud
y
N
D
es
ig
n
Pa
tie
nt
sN
Re
su
lts
P
va
lu
e
N
N
T
(9
5%
CI
)
Bo
tto
m
lin
e
In
te
rv
en
tio
n
C
on
tro
l
O
dd
sR
at
io
(9
5%
CI
)
𝜔
-3
-P
U
FA
s
M
oz
aff
ar
ia
n
et
al
.
[5
6]
20
12
RC
T
PO
A
F
1R
CT
75
8
75
8
0.
96
(0
.7
7
to
1.2
0)
0.
74
N
A
𝜔
-3
-P
U
FA
sa
re
no
t
be
ne
fic
ia
l
St
ro
ke
1R
CT
75
8
75
8
0.
45
(0
.13
to
1.5
1)
0.
18
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
st
ro
ke
M
or
ta
lit
y
1R
CT
75
8
75
8
0.
53
(0
.2
3
to
1.2
6)
0.
14
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
(C
V
)m
or
ta
lit
y
CV
m
or
ta
lit
y
1R
CT
75
8
75
8
N
A
0.
08
N
A
N
o
sig
ni
fic
an
td
ec
re
as
e
in
ho
sp
ita
ls
ta
y
H
os
pi
ta
ls
ta
y
1R
CT
75
8
75
8
N
A
0.
48
N
A
Li
u
et
al
.
[5
7]
20
11
M
A
PO
A
F
10
RC
Ts
97
7
97
8
0.
81
(0
.5
7
to
1.1
5)
0.
24
N
A
𝜔
-3
-P
U
FA
sa
re
no
t
be
ne
fic
ia
l
M
oz
aff
ar
ia
n
et
al
.
[5
8]
20
13
M
A
PO
A
F
8
RC
Ts
27
17
N
A
0.
85
(0
.7
2
to
1.0
0)
0.
24
N
A
𝜔
-3
-P
U
FA
sa
re
no
t
be
ne
fic
ia
l
PO
A
F:
po
sto
pe
ra
tiv
ea
tr
ia
lfi
br
ill
at
io
n;
N
A
:N
ot
ap
pl
ic
ab
le
;N
N
T:
nu
m
be
rn
ee
de
d
to
tre
at
;N
N
H
:n
um
be
rn
ee
de
d
to
ha
rm
;h
rs
:h
ou
rs
;r
ef
.:
re
fe
re
nc
e;
po
sto
p:
po
sto
pe
ra
tiv
e;
pr
eo
p:
pr
eo
pe
ra
tiv
e;
RC
T:
ra
nd
om
iz
ed
co
nt
ro
lt
ria
l;
M
A
:m
et
a-
an
al
ys
is.
12 Cardiology Research and Practice
after cardiac surgery [3, 43, 45]. Potential adverse events of 𝛽
blocker therapy include sinus bradycardia (3%), hypotension
(1%), decompensate congestive heart failure exacerbation
(<1%), and bronchospasm (rare) [43]. Patients with inotropic
maintenance, hemodynamic compromise, second or third
degree atrioventricular block, or chronic lung disease are
generally contraindicated with regard to 𝛽 blocker therapy.
The ACC/AHA Guidelines recommend that in the
absence of contraindications, 𝛽-blocker therapy should be
applied to patients undergoing cardiac surgery (class I, level
A) [34]. Oral 𝛽-Blocker therapy should be administrated
at least 1 week before cardiac surgery with a 𝛽1-blocker
nonintrinsic sympathomimetic effect if possible (class I, level
B) [43, 45].
5.2.2. Amiodarone. Amiodarone is a multichannel (K+, Na+,
and Ca2+) blocking agent and is considered a class III anti-
arrhythmic drug.
Although the variations in dose, duration, and routes of
delivery exist, large meta-analyses demonstrated a beneficial
effect of amiodarone therapy in regard to POAF prevention.
A recent meta-analysis of 33 studies on 5402 patients
demonstrated a significant reduction with respect to the
incidence of POAF with an absolute risk ratio of 14% (OR
0.43 95%CI 0.34 to 0.54; 𝑃 < 0.00001; NNT = 8). Addi-
tionally, it demonstrated a shorter length hospital stay in the
amiodarone group. Despite these results, no significant risk
reduction was observed in stroke, postoperative mortality,
and cardiovascular mortality [43].
A recent meta-analysis indicated that the effect of amio-
darone in prevention of POAF was independent in regard to
the route and timing of drug administration and duration of
treatment, when at least 300mg of intravenous amiodarone
was given followed by an administration of a total dose of 1 g
[47].
On the other hand, several meta-analyses did report
an increased risk of postoperative adverse events including
postoperative bradycardia and hypotension (16%). Other
known adverse events include increase in serum creatinine
(93%), phlebitis of administration site, ventricular arrhyth-
mias (2% to 5%), and hepatotoxicity (3% to 20%) [43].
Adverse effects of amiodarone seem to be related to dose and
should therefore be given in the lowest dose for a short period
if possible. Regimens containing i.v. amiodarone, initiating
prophylaxis during the postoperative period, and regimens
with average daily doses exceeding 1 g were all associated
with an increased risk of adverse events [60]. In addition,
combination therapy of amiodarone and 𝛽 blocker therapy
increased the risk of developing these adverse events [60].
The ACC/AHA Guidelines recommend that patients who
are at high risk for POAF and who have a contraindication
for 𝛽-blocker therapy should consider having prophylactic
amiodarone therapy during the preoperative administration
to prevent POAF (IIa, level A).
5.2.3. Sotalol. Sotalol is a nonselective 𝛽-blocker drug also
having a class III action of prolonging repolarization by
blocking cardiacK+ channels and decreasing neurohormonal
activation.
It has been reported in a recent meta-analysis of 11 studies
on 1609 patients that sotalol therapy reduced POAF with
an absolute risk reduction of 21.9% compared with placebo
(OR 0.34; 95%CI 0.26 to 0.43; 𝑃 < 0.00001; NNT = 5).
Up to 55% of the included studies administrated sotalol
postoperatively. However, no risk reduction was observed in
stroke, cardiovascular mortality, and length of stay [43].
Also, a meta-analysis demonstrated that sotalol therapy
is more effective in POAF prevention compared to placebo
(OR 0.55; 95%CI 0.45 to 0.67; 𝑃 < 0.001; NNT = 6), no
treatment (OR 0.33 95%CI 0.24 to 0.46; 𝑃 < 0.001; NNT =
4), or 𝛽-Blocker therapy (OR 0.60; 95%CI 0.50 to 0.84; 𝑃 <
0.001; NNT = 12). Preoperative sotalol administration was
accompaniedwithmore discontinuation due to drug induced
adverse effects and also provided no advantage compared to
postoperative sotalol administration [48].
Both meta-analyses reported a significantly shorter
length of hospital stay in the sotalol group compared to the
control groups [43, 48].
Several known adverse side effects have been reported in
patients with sotalol therapy after cardiac surgery, including
hypotension (6%), dyspnea (21%), bradycardia (16%), and
supraventricular arrhythmia (4%) [43]. Due to the most
significant complication, Torsade de pointes, prophylactic
sotalol drug therapy for POAF must be used with caution,
especially in patients who have electrolyte disturbances,
prolongedQ-T interval, and supraventricular arrhythmia [61,
62].The ACC/AHAGuidelines recommend the utilization of
sotalol therapy only in high risk patients and in the absence
of contraindications (level IIb, B).
5.3. Upstream Therapies. Upstream therapy is defined as
the utilization of a nonantiarrhythmic treatment that could
alter the atrial substrate or any additional target-specific
mechanisms of POAF including inflammation reduction.
This is desirable for patients with bradycardia and heart
failure who are contraindicated to 𝛽-blocker therapy. Despite
having their own side effects, some of these upstream drug
therapies have shown to be effective in reducing the incidence
of POAF. Statins (HMG-CO-A inhibitors), corticosteroids,
magnesium, and 𝜔-3 fatty acids will be discussed (Table 4).
5.3.1. Statins. Statins are lipid-lowering drugs that have a
large variety of actions including anti-inflammation abilities.
This anti-inflammatory effect may reduce the incidence of
POAF. A recent meta-analysis of 11 studies that compared
preoperative statin therapy with a control group (no statin
medication or placebo) in 984 patients who underwent
predominantly CABG surgery showed a significant risk
reduction of POAF in the statin group with an absolute risk
reduction of 17% (OR 0.40; 95%CI: 0.29 to 0.55; 𝑃 < 0.01;
NNT = 7). There were no major or minor perioperative side-
effects reported with respect to safety endpoint. However, it
failed to demonstrate a significant risk reduction in stroke
and postoperative mortality [50]. Other meta-analyses have
demonstrated a significant reduction of ICU stay and length
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of hospital stay in patient who received preoperative statin
therapy [50, 52].
Another recent meta-analysis of 9 studies on 933 patients
undergoing CABG procedures also showed also a beneficial
effect of statin with regard to POAF prevention (OR 0.56;
95%CI 0.45 to 0.69; 𝑃 < 0.0001; NNT = 7) [51]. In
addition, this was confirmed in an additional meta-analysis
of 8 studies on 774 patients evaluating statin therapy for
developing AF after cardiac surgery (OR 0.57; 95%CI 0.45
to 0.72; 𝑃 < 0.0006; NNT = 6). In this same study, a meta-
regression analysis showed an association between duration
of preoperative statin prophylaxis and POAF reduction with
3% reduction per day (𝑃 = 0.008). No association was
observed between statin dose and risk reduction in POAF
(𝑃 = 0.47) [52].
Currently, the ACC/AHAGuidelines recommend that all
patients undergoing CABG procedure should receive statin
therapy regardless of their lipid profile in the preoperative
period including a direct continuation of statin therapy in
the postoperative phase (class I, level A) [63]. Although
current guidelines do not particularly recommend the uti-
lization of statin therapy to prevent AF after cardiac surgery,
current evidence suggests that preoperative statin therapy
is associated with a reduction in risk of developing POAF.
Therefore, prophylactic statin administration in all patients
who tolerate statins at least a week before cardiac surgery for
POAF prevention is validated.
5.3.2. Magnesium. Patients with hypomagnesemia are more
at risk of developing AF after cardiac surgery [64, 65].
The utilization of prophylactic magnesium during cardiac
surgery could therefore correct the magnesium deficiency
and potentially prevent the development of POAF.
A recent meta-analysis of 21 studies involving 2988
patients with the majority receiving CABG demonstrated
that magnesium therapy decreased the risk of POAF with
an absolute risk reduction of 10% (OR 0.55; 95%CI 0.41
to 0.73; 𝑃 < 0.0001; NNT = 11). While dosing regimens
varied amongst the included studies, all studies administrated
magnesium therapy intravenously and with the majority of
the studies (57%) utilizingmagnesium therapy in the intraop-
erative phase [43]. Identical results were reported in another
meta-analysis of 15 studies on patients who underwent a
CABG procedure (OR 0.61; 95%CI 0.41 to 0.90; 𝑃 < 0.0001;
NNT = 13) [49]. Magnesium therapy did not demonstrate a
significant risk reduction in stroke, postoperative mortality,
and length of hospital stay [43]. Generally, i.v. magnesium
administration is associated with few adverse events when
a normal renal function is present [66]. Although current
guidelines have not yet recommendedmagnesium therapy as
a standard prophylactic option for the prevention of AF after
cardiac surgery, it seems that the utilization of magnesium
therapy in the perioperative setting could be considered an
option for POAF prevention.
5.3.3. Corticosteroids. Because of the anti-inflammatory
properties of corticosteroids, several studies have investigated
whether corticosteroids could potentially reduce the risk of
AF after cardiac surgery.
A meta-analysis of 18 studies on 1509 patients demon-
strated a significant reduction in developing AF after cardiac
surgery (RR 0.74; 95%CI 0.63 to 0.86; 𝑃 = 0.0001;
NNT = 10). No significant difference was observed between
different doses of corticosteroids administration. However,
an increased risk was observed in the corticosteroids group
compared to placebowith respect to hyperglycemia requiring
insulin infusion when a high dose of corticosteroids was
utilized (>10,000mg hydrocortisone; NNT = 9) although no
increased risk was observed in postoperative mortality (𝑃 =
0.16) and infection (𝑃 = 0.73) [53].
A recent meta-analysis of 17 studies involving 1389
patients who underwent CABG surgery showed a reduction
of POAF with an absolute risk of 11% in the corticosteroid
group compared to placebo (OR 0.60; 95%CI 0.46 to 0.78;
𝑃 = 0.00016; NNT = 13). Both low and high dose of cor-
ticosteroids initiation demonstrated the same effect. A sig-
nificant reduction was also demonstrated in ICU stay. The
utilization of corticosteroids had no significant impact on
postoperative mortality, stroke, and infections. However, the
authors concluded that because 𝛽-blocker therapy is associ-
ated with a smaller amount of side effects than corticosteroid
administration, the distinctive reduction of POAFwas not an
indication for the utilization of corticosteroid therapy [54].
Conversely, a recent RCT (DECS trial) consisting of
4482 patients who received either intraoperative high-dose
dexamethasone or placebo demonstrated no beneficial effect
of dexamethasone compared to placebo with respect to risk
reduction of POAF (OR 0.94; 95%CI 0.87 to 1.02; 𝑃 =
0.14). However, over half of the included patients in both
cohorts were utilizing 𝛽-blocker and statin therapy before
cardiac surgery. While a reduction in the risk of infections,
length of ICU, and hospital stay was demonstrated in the
dexamethasone group, no decrease in risk was observed with
respect to stroke and postoperative mortality. In addition,
dexamethasone was related to elevated postoperative glucose
levels (𝑃 < 0.001) [55].
Due to the potential adverse effects associated with
corticosteroids, the utilization of this therapy for prevention
of POAF is not a standard therapy at this time.
5.3.4. 𝜔-3 Fatty Acids. Ω-3 Polyunsaturated fatty acids (𝜔-3-
PUFAs) are parts of the biological membrane which produce
a stabilizing effect. Additionally, 𝜔-3-PUFAs have a positive
effect on several ion channels and are known to reduce
inflammation, oxidative stress, atrial electrical remodelling,
and rarefy structural atria alternations.
A meta-analysis of 10 studies involving 1955 patients
showed that 𝜔-3-PUFAs was not effective in the prevention
of POAF (OR 0.81; 95%CI 0.57 to 1.15; 𝑃 = 0.24) [57]. This
was also confirmed in a recent meta-analysis of 8 studies on
2717 patients (OR 0.85; 95%CI 0.72 to 1.00; 𝑃 = 0.24) [58].
A recent multicenter RCT (OPERA-Study) consisting of 1516
patients who received either perioperative supplementation
with 𝜔-3-PUFAs or placebo also failed to demonstrate a risk
reduction of POAF (OR 0.96; 95%CI 0.77 to 1.20; 𝑃 = 0.74).
Ω-3-PUFAs were not associated with major adverse events
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including stroke, postoperative, and cardiovascular mortality
[56]. Current evidence suggests that short-term 𝜔-3-PUFA
use has no effect on POAF prevention after cardiac surgery.
6. Conclusion
Despite numerous management strategies, POAF still
remains amajormedical problem and poses serious risks and
consequences.
The pathogenesis of POAF still remains not fully under-
stood. The multiple wavelet re-entry theory in combination
with certain biochemical mechanisms including neurohor-
monal activation, volume overload, and inflammation is
likely the major contributing factor. Several risk factors have
been described for the development of POAF. Recognizing
these risk factors will aid physicians to take preventative
strategy in high-risk patients.
Current guidelines suggest that when POAF persists for
more than 48 hours, anticoagulation for 30 days with a
vitaminK antagonist should be utilized to achieve an interna-
tional normalizing ratio between 2.0 and 3.0. However, due to
difficultymanaging warfarin, new oral anticoagulants such as
rivaroxaban, apixaban, and dabigatran are viewed as possible
future options. Future studies to assess the risk-benefit ratio
of these medications for the cardiac surgery population may
increase the use of these medications in the near future.
Current evidence suggests that 𝛽-blocker therapy should
be utilized during the perioperative setting in all patients
when contraindications are absent. Amiodarone therapy
could be supplemented in patients who have a high risk of
developing POAF. Due to the known potential side effects,
sotalol therapy should only be administrated to high risk
patients and in the absence of contraindications. When high
risk patients have a contraindication for these antiarrhythmic
drugs, biatrial pacing could be considered. With regard to
statins, it is reasonable to administrate prophylactic statin
therapy in all patients who tolerate statins at least a week
before cardiac surgery. Magnesium therapy, corticosteroids,
and posterior pericardiotomy still remain controversial on
whether the utilization of these interventions could achieve a
risk reduction. Current evidence suggests that short-term 𝜔-
3-PUFA use has no effect on POAF prevention after cardiac
surgery.
In prevention of POAF, understanding of the risk and
pathophysiology and choosing adequate prophylactic option
are the key.
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